Biopharma, US FTC Portray Opposing Sides In Debate Over Patent ‘March-In’ Policy

 
• By Brenda Sandburg
  
Marching band
The Biden Administration proposal to expand the approach to exercising patent march-in rights has drawn thousands of comments. • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin